The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NRIX | +14.75% | -63.88% | -18.43% | -16% |
| S&P | +21.6% | +71.83% | +11.43% | +111% |
Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.
The clinical-stage biopharmaceutical company posted positive news regarding its lead therapy -- a BTK inhibitor that could fight certain blood-based cancers.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $13.58M | 2.2% |
| Gross Profit | $8.95M | -0.4% |
| Gross Margin | 65.89% | -1.7% |
| Market Cap | $1.79B | 14.4% |
| Market Cap / Employee | $5.65M | 0.0% |
| Employees | 317 | 10.8% |
| Net Income | -$78,221.00K | -33.6% |
| EBITDA | -$78,464.00K | -30.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $246.96M | 124.5% |
| Accounts Receivable | $19.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $52.91M | 160.8% |
| Short Term Debt | $2.82M | -64.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -38.38% | -1.2% |
| Return On Invested Capital | -41.23% | -52.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$72,963.00K | -43.5% |
| Operating Free Cash Flow | -$67,832.00K | -39.1% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.22 | 1.69 | 1.59 | 3.65 | -7.24% |
| Price to Sales | 22.88 | 10.09 | 9.39 | 20.02 | -37.01% |
| Price to Tangible Book Value | 2.22 | 1.69 | 1.59 | 3.65 | -7.24% |
| Enterprise Value to EBITDA | -13.07 | -10.59 | -4.79 | -14.58 | -23.64% |
| Return on Equity | -64.2% | -50.7% | -65.4% | -49.6% | -6.74% |
| Total Debt | $26.62M | $51.93M | $56.49M | $55.73M | 96.90% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
